Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT06586515

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Led by Eli Lilly and Company · Updated on 2026-04-20

630

Participants Needed

52

Research Sites

233 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

CONDITIONS

Official Title

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Have histological or cytological confirmation of locally advanced, unresectable, and/or metastatic cancer with measurable disease per RECIST version 1.1
  • Have evidence of KRAS G12D mutation in tumor tissue or circulating tumor DNA
  • Have an ECOG performance status of 1 or less
  • Have received at least one prior line of systemic chemotherapy for advanced or metastatic disease
  • Participants with asymptomatic or treated central nervous system disease may be eligible
Not Eligible

You will not qualify if you...

  • Have known active central nervous system metastases or carcinomatous meningitis
  • Have unresolved toxicities from prior therapy greater than NCI CTCAE version 5.0 Grade 1
  • Have significant cardiovascular disease such as unstable angina, acute coronary syndrome, history of myocardial infarction, or known reduced left ventricular ejection fraction
  • Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
  • Have known active hepatitis B virus or hepatitis C virus infection
  • Have other active malignancy unless in remission with life expectancy greater than 2 years

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 52 locations

1

City of Hope

Duarte, California, United States, 91010

Actively Recruiting

2

University of California, Los Angeles (UCLA)

Santa Monica, California, United States, 90404

Actively Recruiting

3

Sarah Cannon Research Institute at HealthOne

Denver, Colorado, United States, 80218

Actively Recruiting

4

Sibley Memorial Hospital

Washington D.C., District of Columbia, United States, 20016

Actively Recruiting

5

Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute

Orlando, Florida, United States, 32827

Actively Recruiting

6

Emory University School of Medicine

Atlanta, Georgia, United States, 30322

Actively Recruiting

7

Community Health Network

Indianapolis, Indiana, United States, 46250

Actively Recruiting

8

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Not Yet Recruiting

9

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Actively Recruiting

10

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States, 48201

Actively Recruiting

11

South Texas Accelerated Research Therapeutics (START) Midwest

Grand Rapids, Michigan, United States, 49546

Actively Recruiting

12

New York University (NYU) Langone Medical Center

New York, New York, United States, 10016

Actively Recruiting

13

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Actively Recruiting

14

Duke University Medical Center

Durham, North Carolina, United States, 27710

Actively Recruiting

15

University of Cincinnati (UC) - Cancer Institute

Cincinnati, Ohio, United States, 45267

Actively Recruiting

16

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Actively Recruiting

17

University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center

Pittsburgh, Pennsylvania, United States, 15232

Actively Recruiting

18

Sarah Cannon Research Institute

Nashville, Tennessee, United States, 37203

Actively Recruiting

19

USO - US Oncology Research Network

Nashville, Tennessee, United States, 37203

Actively Recruiting

20

Vanderbilt University School of Medicine

Nashville, Tennessee, United States, 37215

Actively Recruiting

21

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

22

South Texas Accelerated Research Therapeutics (START)

San Antonio, Texas, United States, 78229

Actively Recruiting

23

Huntsman Cancer Institute

Salt Lake City, Utah, United States, 84112

Actively Recruiting

24

Fred Hutchinson Cancer Center

Seattle, Washington, United States, 98109

Actively Recruiting

25

University of Wisconsin - Carbone Cancer Center

Madison, Wisconsin, United States, 53792

Actively Recruiting

26

The Ottawa Hospital

Ottawa, Canada, K1H 8L6

Actively Recruiting

27

Princess Margaret Hospital

Toronto, Canada, M5G 2M9

Actively Recruiting

28

Cancer Institute & Hospital, Chinese Academy of Medical Sciences

Beijing, China, 100021

Not Yet Recruiting

29

Beijing Cancer hospital

Beijing, China, 100142

Not Yet Recruiting

30

Harbin Medical University Cancer Hospita

Harbin, China, 150081

Not Yet Recruiting

31

Fudan University Cancer Center

Shanghai, China, 200032

Not Yet Recruiting

32

Centre Leon Berard

Lyon, France, 69373

Not Yet Recruiting

33

Centre d'Essais Precoces en Cancerologie de Marseille (CEPCM) - AP-HM Hopital de La Timone

Marseille, France, 13005

Not Yet Recruiting

34

Oncopole Claudius Regaud

Toulouse, France, 31059

Not Yet Recruiting

35

Institut Gustave Roussy

Villejuif, France, 94805

Not Yet Recruiting

36

Charite Universitaetsmedizin Berlin

Berlin, Germany, 10117

Actively Recruiting

37

Universitaetsklinikum Carl Gustav Carus Dresden

Dresden, Germany, 01307

Actively Recruiting

38

Universitaetsklinikum Essen

Essen, Germany, 45147

Actively Recruiting

39

Klinikum der Ludwig-Maximilians-Universitaet Muenchen

München, Germany, 81377

Actively Recruiting

40

START Dublin Early Phase Clinical Trials Unit

Dublin, Ireland, D07 R2WY

Actively Recruiting

41

Azienda Ospedaliera Universitaria - Universita degli Studi della Campania Luigi Vanvitelli

Naples, Italy, 80138

Actively Recruiting

42

UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

Roma, Italy, 00168

Actively Recruiting

43

Centro Ricerche Cliniche di Verona s.r.l.

Verona, Italy, 37134

Actively Recruiting

44

National Cancer Center Hospital East

Chiba, Japan, 277-8577

Actively Recruiting

45

Kanagawa cancer center

Kanagawa, Japan, 241-8515

Actively Recruiting

46

Aichi Cancer Center Hospital

Nagoya, Japan, 464-8681

Actively Recruiting

47

Kansai Medical University Hospital

Osaka, Japan, 573-1191

Actively Recruiting

48

National Cancer Center Hospital

Tokyo, Japan, 104-0045

Actively Recruiting

49

South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos

Barcelona, Spain, 08023

Actively Recruiting

50

Hospital Universitario Vall d'Hebron

Barcelona, Spain, 08035

Actively Recruiting

51

South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz

Madrid, Spain, 28040

Actively Recruiting

52

Hospital Universitario 12 de Octubre

Madrid, Spain, 28041

Actively Recruiting

Loading map...

Research Team

T

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

CONTACT

P

Physicians interested in becoming principal investigators please contact

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | DecenTrialz